Clinical trial
Methylene Blue for Cognitive Dysfunction in Bipolar Disorder
NCT00214877 · Nova Scotia Health Authority, Other · Completed
Key facts
| NCT number | NCT00214877 |
|---|---|
| Title | Methylene Blue for Cognitive Dysfunction in Bipolar Disorder |
| Official title | Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder |
| Lead sponsor | Nova Scotia Health Authority, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Methylene Blue |
| Enrollment | 40 |
| Start date | Nov 1, 2003 |
| Completion | Oct 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 1, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: